Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SRF617 |
Synonyms | |
Therapy Description |
SRF617 is a monoclonal antibody that binds to CD39 and inhibits the conversion of ATP to AMP, potentially resulting in enhanced adaptive and innate immune response against tumor cells (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SRF617 | SRF-617|SRF 617 | CD39 Antibody 5 | SRF617 is a monoclonal antibody that binds to CD39 and inhibits the conversion of ATP to AMP, potentially resulting in enhanced adaptive and innate immune response against tumor cells (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04336098 | Phase I | SRF617 | Study of SRF617 in Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |